We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Instruments Plc | LSE:OXIG | London | Ordinary Share | GB0006650450 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 55.00 | 2.38% | 2,365.00 | 2,360.00 | 2,370.00 | 2,380.00 | 2,255.00 | 2,255.00 | 20,093 | 14:22:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Lab Analytical Instruments | 444.7M | 58.6M | 1.0126 | 23.50 | 1.38B |
From May 2019 to May 2024
TIDMOXIG
RNS Number : 3816W
Oxford Instruments PLC
14 November 2017
Release Date: 7am Tuesday 14 November 2017
Oxford Instruments plc
Announcement of Half Year Results for the six months to 30 September 2017
Oxford Instruments plc, a leading provider of high technology products and systems for industry and research, today announces its Half Year Results for the six months to 30 September 2017.
Hot Features
Premium
Half year to Half year to % change
30 September 30 September
2017 2016
GBPm GBPm
Revenue(1) 132.1 132.4 -0.2%
Adjusted* operating profit(1) 18.8 16.4 +14.6%
Adjusted* profit before tax(1) 16.3 13.1 +24.4%
Profit/(loss) before tax(1) 12.7 (0.6)
Adjusted* basic earnings per share(1) 22.3p 18.0p +23.9%
Dividend per share (interim) 3.7p 3.7p
Operating cash flow(1) 4.1 2.0
Net debt 45.5 141.1
(1) Continuing operations
Financial Highlights:
-- Reported orders up 6.0% to GBP148.5 million (2016: GBP140.1 million), an increase of 1.8% at constant currency
-- Reported revenue in line with previous year, down 4.5% at constant currency
-- Adjusted profit before tax from continuing operations up 24.4% to GBP16.3 million (2016: GBP13.1 million)
-- Adjusted operating margin up 180 basis points primarily reflecting currency benefits
-- Profit before tax from continuing operations of GBP12.7 million (2016: loss of GBP0.6 million)
-- Constant currency order book of GBP141.8 million up 3.3% and 11.8% against September 2016 and March 2017 respectively
-- Significantly strengthened balance sheet with proceeds from sale of Industrial Analysis leading to reduction in net debt to GBP45.5m (2016: GBP141.1 million)
-- Interim dividend maintained at 3.7 pence
Operational Highlights:
-- Implementation of Horizon Strategy is progressing, repositioning the Group for long term growth and margin improvement, building on our world-class nanotechnology expertise
-- Building management, leadership and core capabilities across the Group -- Portfolio management progress with sale of Industrial Analysis completed in July 2017
-- New market focused structure to align the Group's management and reporting sectors with our customer and application focus, and to deliver synergies and benefits across the Group:
-- Materials & Characterisation: focuses on applied R&D and commercial customers, enabling the fabrication and characterisation of materials and devices down to the atomic scale
-- Research & Discovery: advanced solutions that create unique environments and enable measurements down to the molecular and atomic level, used in fundamental and applied research
-- Service & Healthcare: provides customer service and support for our own products and the service, sale and rental of third party healthcare imaging systems
-- Continued investment in innovation with R&D spend maintained at 9.8% of revenue -- Appointment of Steve Blair as Senior Independent Director
Ian Barkshire, Chief Executive of Oxford Instruments plc, said:
"Our customers recognise us as key enablers of their strategies. As such, we are enjoying increasingly collaborative commercial relationships, delivering solutions that enable them to succeed at the frontiers of science and within applied R&D and commercial applications.
"Our new reporting structure enhances our focus on the growth drivers of our markets and the evolving demands of our customers and will drive cross-business synergies.
"Our expectations for the current financial year remain unchanged, supported by growth in constant currency orders and order book, the timing of new product introductions, our normal second half seasonal bias and favourable currency effects.
"I am encouraged by the progress we have made in the early stages of implementing the Horizon strategy, providing confidence in the longer term delivery of sustainable revenue growth and margin improvement."
Enquiries:
Oxford Instruments plc Tel: 01865 393200
Ian Barkshire, Chief Executive
Gavin Hill, Group Finance Director
MHP Communications Tel: 020 3128 8100
Rachel Hirst / Luke Briggs
Number of pages: 39
*NOTE: Throughout this half year announcement we make reference to adjusted numbers. These are presented as, in the opinion of the Directors, they present a clearer picture of the business performance. A full definition of adjusted numbers can be found in note 2. Where we make reference to constant currency numbers these are prepared using the exchange rates which prevailed in the previous year rather than the actual exchange rates which prevailed in the year.
Chief Executive's Review
Overview
We have made good progress in the initial implementation stages of our Horizon strategy whilst maintaining a focus on the near term delivery.
We have continued our proactive approach to portfolio management, successfully completing the disposal of the Industrial Analysis business in July. As a more focused nanotechnology Group, we have reorganised our structure in line with our chosen customer segments and applications.
Our three new reporting sectors - Materials & Characterisation, Research & Discovery, and Service & Healthcare - include business units with the same end-markets, enabling us to deliver higher value to our customers and drive synergies and efficiencies across the Group.
Reported orders for the Group were up 6.0% (1.8% at constant currency) to GBP148.5 million (2016: GBP140.1 million), with growth in both Materials & Characterisation and Research & Discovery, partially offset by lower orders in our Service & Healthcare sector due to fewer orders in our US Healthcare business.
Reported revenue was broadly in line with last year at GBP132.1 million (2016: GBP132.4 million), down 4.5% at constant currency. Adjusted operating profit was up 14.6% to GBP18.8 million (2016: GBP16.4 million), although down 12.2% at constant currency, with a strong performance in Materials & Characterisation and growth in Service & Healthcare offset by reduced volumes in Research & Discovery.
The order book, representing orders for future delivery, as at 30 September 2017 increased 11.8% at constant currency since the year end and is up 3.3% at constant currency on the prior half year.
Continuing adjusted basic earnings per share increased by 23.9% to 22.3p. The dividend is maintained at 3.7 pence, in line with last year.
The proceeds from the sale of Industrial Analysis have significantly strengthened the balance sheet with net debt at the end of the period reduced to GBP45.5 million, down from GBP109.3 million at year end.
Horizon Strategy Progress
We introduced our Horizon Strategy in June, outlining how it will help us achieve sustainable revenue growth and margin improvement. Horizon focuses the Group on those markets where nanotechnology will provide long-term growth drivers for our customers and where we have the opportunity to achieve or maintain market leadership. We provide value for our customers by offering solutions that enable them to be successful, tailoring our products and services to help them meet their current and future needs.
Our customers are at the centre of our focus, and I previously outlined the key capabilities that we are embedding across our organisation. These are market intimacy, innovation and product development, customer support, and operational excellence.
While it is still early in our Horizon journey we have made good progress in a number of areas in support of our new strategy. We have undertaken significant management of the portfolio, successfully completing the sale of Industrial Analysis in July, making us a more focused nanotechnology Group. We are building the management, leadership and core capabilities across the Group to enable us to deliver the Horizon strategy. Of the 40 top level leaders in the Group, 37% have been appointed since September 2016; and we recently recruited a US based Group Commercial Director to establish sales best practice globally. We continue to target experienced leaders from a range of different markets and disciplines to help us build on our capabilities.
A core part of the Horizon strategy is the transition of the Group from a product and technique focus to being customer application and market focused. Our new structure aligns our business operations, management and reporting sectors with our chosen market and customers' applications. It is also helping us build stronger relationships with our customers and will drive future synergies across and within the businesses. The Materials & Characterisation sector comprises our Asylum Research, NanoAnalysis and Plasma Technology businesses. Research & Discovery includes Andor Technology, NanoScience (including Magnetic Resonance), X-ray Technology and ScientaOmicron. Our Service & Healthcare sector remains OiService and OI Healthcare.
Our new market focus structure is aligned with serving our core end markets in Healthcare & Life Science; Semiconductor & Communications; Quantum Technology; Environment; Energy; Advanced Materials; and Research & Fundamental Science. Beneath this top tier we have identified and are actively focusing on a number of specific niche segments that present particularly attractive growth opportunities.
We have also made good progress embedding our operating model, standardising a number of processes against best practice, and ensuring that we are leveraging the expertise we have across the Group to increased effect.
Our customers recognise us as key enablers of their strategies. As such, we are enjoying increasingly collaborative commercial relationships, delivering solutions that enable them to succeed within fundamental research, applied R&D and commercial applications. Our new reporting structure enhances our focus on the growth drivers of our markets and the evolving demands of our customers and will drive cross-business synergies.
Sector Performance
Turning to the performance of our individual sectors:
Materials & Characterisation focuses on applied R&D and commercial customers, enabling the fabrication and characterisation of materials and devices down to the atomic scale. This sector delivered a strong first half, with positive contributions from the NanoAnalysis, Plasma Technology and Asylum Research businesses. Reported revenue increased by 10.6% to GBP50.1 million (2016: GBP45.3 million), with reported adjusted operating profit increasing to GBP7.2 million (2016: GBP4.2 million). Furthermore, strong reported order growth of 25.8% to GBP61.9 million (2016: GBP49.2 million) provided positive order book growth for future deliveries. The enhanced results were driven by strong demand for recently launched higher margin products, an increased focus on end customer applications and operational efficiencies. In particular, we saw increased demand for our semiconductor and advanced materials processing solutions and our portfolio of scanning probe microscopes.
Research & Discovery provides advanced solutions that create unique environments and enable measurements down to the molecular and atomic level, used in fundamental and applied research. This sector saw increased orders in the period of GBP57.8 million (2016: GBP54.3 million), up 6.4% on a reported basis driven, in part, by growth in quantum related research applications and increased demand for our benchtop NMR products. Revenues of GBP48.0 million were down 13.4% on the previous year (2016: GBP55.4 million). This was due firstly to a softer financial performance from the optical microscopy products in Andor Technology as we transition from third party systems to our own portfolio. In addition, the higher proportion of longer lead time customised cryogenic and magnet system orders with lower margins in NanoScience is depressing financial performance. We are at the early stages of addressing this by moving towards a greater proportion of revenue derived from standardised systems.
Service & Healthcare provides customer service and support for our own products and the service, sale and rental of third party healthcare imaging systems. This sector increased reported revenue by 7.6% to GBP34.1 million, up 2.5% at constant currency (2016: GBP31.7 million) driven by strong demand for services related to our own products. Reported adjusted operating profit increased 42.3% to GBP7.4 million, representing an increase at constant currency of 34.6%, supported by an increased contribution from services for our own products and healthcare related services for third party equipment. Increased orders for services relating to our own products were more than offset by reduced orders for refurbished equipment from our US Healthcare business due to a combination of phasing and previously reported structural changes in the market. Our strategy is to move the US Healthcare business towards a higher proportion of service revenue.
R&D
Innovation remains core to our Horizon strategy and we continue to invest in solutions and technology that help our customers improve their productivity and develop new capabilities. We have maintained our level of investment in R&D initiatives at GBP13.0 million (2016: GBP13.0 million), equivalent to 9.8% of revenue (2016: 9.8%).
People
It is our talented people that make us successful and our thanks go to all our employees for their support and dedication to helping Oxford Instruments support our customers.
Dividends
The Board has declared an interim dividend of 3.7 pence per share (2016: 3.7 pence), in line with last year.
Current Trading and Outlook
Our full year expectations remain unchanged, supported by growth in constant currency orders and order book, the timing of new product introductions, our normal second half seasonal bias and favourable currency effects.
We are encouraged by the early progress in the implementation of the Horizon strategy, providing confidence in the longer term delivery of sustainable revenue growth and margin improvement.
Ian Barkshire
Chief Executive
14 November 2017
Operations Review
As outlined above, our Group now reports in the following three sectors: Materials & Characterisation, Research & Discovery, and Service & Healthcare.
Materials & Characterisation
2017 2016 Growth Constant
GBPm GBPm Currency
Growth(1)
------------------------------ ------ ------ ------- -----------
Revenue 50.1 45.3 10.6% 6.6%
------------------------------ ------ ------ ------- -----------
Adjusted(2) operating profit 7.2 4.2
------------------------------ ------ ------
Adjusted(2) operating margin 14.4% 9.3%
------------------------------ ------ ------
Profit before tax after
adjusting items 5.8 2.1
------------------------------ ------ ------
(1) For definition refer to note on page 2 of highlights
(2) Details of adjusting items can be found in Note 2 of these Financial Statements
The Materials & Characterisation sector is comprised of Asylum Research, NanoAnalysis and Plasma Technology. This sector focuses on applied R&D and commercial customers, enabling the fabrication and characterisation of materials and devices down to the atomic scale. Our products are used across a broad range of applications, for example those undertaking work with semiconductors, photonic devices, metals and polymers, exploring fundamental properties through to regulatory quality assurance (QA) and quality control (QC). We continue to aid fundamental understanding in these areas to facilitate the development of new devices as well as the next generation of higher functioning, stronger and lighter materials. Revenue in Materials & Characterisation comes from a broad range of end applications with about 74% from Semiconductor & Communications and Advanced Materials related customer segments. Industrial and commercial customers represent about 48% of revenue, with the balance from academic and government funded customers.
In the first half Materials & Characterisation continued to show improvement with increased orders, revenue and profitability driven by strong demand for recently launched products and an energised focus on customer applications.
Asylum Research is the technology leader in scanning probe microscopy (SPM) for both materials and bioscience applications. Focusing on the challenges customers face has helped us develop a number of products that have been well received in the market. The Origin+ offers a more affordable and easy to use SPM to the broader market that still wants enhanced capability. We have seen a resurgence in first half orders due to performance enhancements aligned to specific market needs. The recently launched Cypher VRS is providing new insights to researchers exploring disease mechanisms and the efficacy of new medicines. It achieves this by enabling the observation of biological interactions in real time and is the first and only full-featured video rate SPM. We are also seeing increased interest in our solutions for advanced materials, energy production and storage applications.
NanoAnalysis delivers innovative solutions that enable materials characterisation and manipulation at the nanoscale within electron microscopes and ion-beam systems. Our products determine the material properties of plastics through to advanced aerospace components and quantum devices. A steady half year of growth in both orders and revenue was supported by two major product launches. Symmetry, our super-fast material structure analyser, is providing major productivity improvements for customers researching and manufacturing semiconductors and advanced materials for example in the automotive, aerospace and high performance steel markets. Symmetry overcomes the technological barriers of incumbent technology enabling significantly higher quality of data at much higher speeds.
The newly launched Ultim detectors are providing increased capabilities and productivity for customers developing advanced materials, semiconductors and batteries by delivering unparalleled analysis speed and sensitivity. Product innovations continue to drive new capabilities and productivity improvements across a diverse range of end customer applications.
Plasma Technology provides advanced material etch and deposition processes and solutions to semiconductor research laboratories and advanced specialised production facilities that exploit nanotechnology for a range of applications including laser devices, plastic electronics, high brightness laser emitting diodes (LEDs) and microelectromechanical systems (MEMs) for sensors and life science applications. A strong first half was supported by favourable general market conditions. We have seen significantly increased interest in the optoelectronics device market, where our customers are developing laser and photonic devices that are key to enabling the increased data communication rates resulting from increased device connectivity and usage through the development and ramp up for 5G networking. Our expertise in the advanced processing of compound semiconductors provides the foundation for growth within, and expansion into, related specialised production markets.
Research & Discovery
2017 2016 Growth Constant
GBPm GBPm Currency
Growth(1)
------------------------- ------ ------ -------- -----------
Revenue 48.0 55.4 (13.4%) (17.5%)
------------------------- ------ ------ -------- -----------
Adjusted(2) operating
profit 4.2 7.0
------------------------- ------ ------
Adjusted(2) operating
margin 8.8% 12.6%
------------------------- ------ ------
Profit before tax after
adjusting items 0.1 2.9
------------------------- ------ ------
(1) For definition refer to note on page 2 of highlights
(2) Details of adjusting items can be found in Note 2 of these Financial Statements
The Research & Discovery sector includes Andor Technology, Magnetic Resonance, NanoScience, X-ray Technology and our minority share in ScientaOmicron. This sector provides advanced solutions that create unique environments and enable measurements down to the molecular and atomic level, used in fundamental and applied research. We are able to build on our relationships with customers working on breakthrough applications in research to gain insights and support future commercial applications.
In this sector, 42% of revenue comes from customers working within Healthcare & Life Science applications. Customers exploring new semiconductor materials and devices make a significant contribution, and an increasing share is coming from customers working in quantum technology applications and research. Quantum Technology is a strong growth area for the sector due to increased government and corporate funding including applications such as quantum information processing and quantum sensors. Research & Fundamental Science contributes 4% of revenue. The sector has a higher proportion of revenue from academic and government funded customers at 72%, with 28% from commercial and industrial customers.
This sector saw an increase in orders in the period but with lower revenue and profitability due to softer financial performance from our optical microscopy products in Andor Technology and a higher proportion of longer production lead time specialist system orders from NanoScience.
Andor Technology is the global leader in the design and manufacture of high performance scientific imaging cameras, spectroscopy solutions and microscopy systems for research and some commercial applications. Revenue is predominately from life science applications with significant contributions from semiconductor materials and astronomy applications. Improved performance from our scientific cameras for astronomy and our imaging analysis software, Imaris, was more than offset by lower sales of our optical microscopy systems, leading to softer financial performance in the half year. The reduction in microscopy sales is due to the transition from third party systems to our own portfolio; increased orders at the back end of the half year, and the launch of the lower price positioned Dragonfly 200, provide positive momentum for the second half of the year. Our Imaris software is enabling customers in cell biology and neuroscience to visualise and interpret the huge data sets that are now being produced by modern microscopy systems. This has driven strong growth for Imaris, which we sell for use with our own and other optical microscopy systems. Our high speed cameras are being deployed in quantum imaging research and we continue to enhance our range of market leading astronomy solutions. Over 25 of our deep cooled cameras were used around the world in the recent and first ever observation of the optical signature of the violent collision of two neutron stars, which were identified by gravitational wave ripples in space-time.
NanoScience designs, manufacturers and supports market-leading products that provide the unique environments critical in fundamental science, the exploitation of many quantum technology applications and new materials and device development in the physical sciences. Strong order growth was driven by government and commercial focus and associated funding into quantum technology, including quantum information processing and sensors. An increase in the proportion of customised magnet and cryogenic systems has depressed financial performance. We are addressing this by moving towards a greater proportion of revenue from standardised systems. We have enhanced our Triton ultra-low temperature cryogenic product range with the launch of "Io", the most compact, affordable and easy to use Cryogenic platform, making this technology available to a wider range of customers, for example those developing low temperature sensor and optical devices.
Magnetic Resonance's easy to operate benchtop NMR solutions provide essential information about the identification and quantification of foods and chemicals for academic and industrial researchers and for QA and QC applications. The business, which was previously within the Industrial Products sector, has been merged into our NanoScience business providing operational efficiencies and broader capabilities to drive future growth. Our enhanced Pulsar and MQC+ systems provide efficiencies compared to wet chemistry and higher cost alternatives, driving strong order growth. In addition, our recently launched GeoSpec rock core analyser is providing increased capabilities for the assessment of economic extraction of oil through its increased sensitivity.
X-ray Technology supplies X-ray sources to leading OEM's for industry, research and medical applications, including material characterisation, real-time medical imaging and analysis of multi-layer printed circuit boards. Growth in healthcare applications was more than offset by a decline from industrial segments.
The ScientaOmicron joint venture created the largest player in the Ultra-High Vacuum surface science field. The Group has a 47% share in the joint venture. The business is showing year on year improvement in its operational and financial performance. During the first half of the year the shareholders completed a refinancing of the business with a rights issue in order to strengthen the balance sheet and provide long-term liquidity.
Service & Healthcare Sector
2017 2016 Growth Constant
GBPm GBPm Currency
Growth(1)
------------------------- ------ ------ ------- -----------
Revenue 34.1 31.7 7.6% 2.5%
------------------------- ------ ------ ------- -----------
Adjusted(2) operating
profit 7.4 5.2
------------------------- ------ ------
Adjusted(2) operating
margin 21.7% 16.4%
------------------------- ------ ------
Profit before tax after
adjusting items 6.7 4.3
------------------------- ------ ------
(1) For definition refer to note on page 2 of highlights
(2) Details of adjusting items can be found in Note 2 of these Financial Statements
The Service & Healthcare sector comprises the Group's maintenance service contracts, billable repairs, training and support services, and spare part sales related to Oxford Instruments' own products under the OiService brand; and the sale, service and rental of refurbished third party MRI and CT machines under the OI Healthcare brand.
Reported revenue increased in the half year, driven predominantly by strong demand for our OiService offerings. Increased orders from OiService were more than offset by reduced orders for refurbished equipment sales within OI Healthcare due to a combination of the timing of sales prospects and previously reported structural changes in the market by OEM providers. Within OiService we continue our drive for enhanced customer support services tailored to their needs, including remote diagnosis and support, and online self-help. Training programmes are designed to maximise increased customer capability and productivity.
For OI Healthcare the first half has been largely focused on management restructuring, allowing us to recruit expert talent from a range of market disciplines. We are currently introducing a new Field Aware project that allows our engineers to provide our customers with real time service updates. We have also recently secured a service contract for a later model GE 3 Tesla MRI scanner. Our strategy is to move the business towards a higher proportion of service contracts and scale back sales of refurbished systems.
Finance Review
During the half year the Group disposed of its Industrial Analysis business and this has been treated as a discontinued operation in the financial statements. Accordingly, the numbers detailed in the Finance Review refer to continuing operations and exclude the results of Industrial Analysis in both the current and prior periods.
Reported revenue was broadly in line with the same period last year at GBP132.1 million (2016: GBP132.4 million). Revenue, excluding currency effects, declined by 4.5%, with the movement in average currency exchange rates over the last year positively impacting reported revenue by GBP5.7 million.
Reported orders increased by 6.0% to GBP148.5 million (2016: GBP140.1 million), an increase of 1.8% at constant currency. At the end of the period the Group's order book for future deliveries stood at GBP141.8 million (2016: GBP140.0 million), growth of 1.3% on a reported basis and 3.3% at constant currency.
Adjusted operating profit from continuing operations increased by 14.6% to GBP18.8 million (2016: GBP16.4 million). Adjusted operating profit from continuing operations, excluding currency effects, declined by 12.2%. This was principally due to two factors: first, the impact from lower first half microscopy revenue, some of which is expected to unwind in the second half of the year; and second, the longer production lead times from our customised magnet and cryogenic systems, compounded by their margins being lower than the business average. As we move to a greater proportion of standardised systems and unwind the more complex orders, we expect the financial performance to improve in the medium term.
Adjusted operating margin from continuing operations increased by 180 basis points to 14.2% (2016: 12.4%), supported by currency benefits and portfolio changes.
Adjusted profit before tax from continuing operations grew by 24.4% to GBP16.3 million (2016: GBP13.1 million). A pre-tax adjusted profit of GBP0.7 million from the Industrial Analysis business for the three months of ownership, prior to its sale on 3 July 2017, is included in discontinued operations. For the six months to 30 September 2016 the Industrial Analysis and Superconducting Wire businesses delivered an operating profit of GBP2.6 million. Including discontinued operations, the Group achieved reported adjusted profit before tax of GBP17.0 million (2016: GBP15.7 million).
Non-recurring items and acquisition related costs were GBP0.6 million, of which GBP0.3 million relates to our Scienta Omicron joint venture. The movement in the mark-to-market valuation of currency hedges for future periods gave rise to a gain of GBP2.6 million.
Adjusted profit before tax from continuing operations of GBP16.3 million (2016: GBP13.1 million) represents a margin of 12.3% (2016: 9.9%). After the amortisation of acquired intangibles, the mark-to-market of derivative financial instruments and other adjusting items, the Group recorded a profit before tax of GBP12.7 million (2016: loss of GBP0.6 million).
Continuing adjusted basic earnings per share grew by 23.9% to 22.3 pence (2016: 18.0 pence). Continuing basic earnings per share was 17.5 pence (2016: loss of 0.9 pence).
Operating cash flow (as defined in section 3.0) increased by GBP2.1 million to GBP4.1 million. Adjusted operating cash (defined as adjusted EBITDA, less movement in working capital, capitalised development expenditure and capital expenditure) represents 10.1% (2016: 3.7%) of adjusted operating profit. Proceeds from the sale of our Industrial Analysis business contributed to a fall in net debt from GBP109.3 million to GBP45.5 million, representing a net debt to EBITDA ratio (for banking covenant purposes) of 0.9 times, well within our banking covenant of 3.0 times.
Adjusted operating profit is stated before impairment and amortisation of goodwill and acquired intangibles, non-recurring items and acquisition-related costs, and the mark-to-market valuation of unexpired currency hedges, as set out in note 2 to the financial statements.
Following the sale of Industrial Analysis we have reorganised the management structure of the Group, resulting in a change to our reporting sectors. NanoAnalysis, Asylum Research and Plasma Technology constitute the Materials & Characterisation sector. Andor Technology, NanoScience and X-ray Technology are included within Research & Discovery, as well as our share of ScientaOmicron. Our Service & Healthcare sector remains unchanged, incorporating the contribution from our Healthcare businesses along with the service revenue and profits of businesses in the other two sectors. The previous NanoTechnology Tools sector comprised the product based results of the businesses within Materials & Characterisation and Research & Discovery with the addition of Magnetic Resonance (now part of NanoScience) and X-ray Technology, both of which were previously part of our Industrial Products sector. Revenue from these businesses for the half year to 30 September 2017 totalled GBP10.2 million (2016: GBP10.8 million) and was GBP22.7 million for the year to 31 March 2017.
The results under the new sectors, including the full year comparative (unaudited) are shown in tables 1 and 2.
Table 1: Sector information: Revenue
Half year Half year Year to
to to 31 March
30 September 30 September 2017
2017 2016 GBPm
GBPm GBPm
------------------------------ -------------- -------------- ----------
Materials & Characterisation 50.1 45.3 104.1
Research & Discovery 47.9 55.4 125.2
Service & Healthcare 34.1 31.7 70.9
Total 132.1 132.4 300.2
------------------------------ -------------- -------------- ----------
Table 2: Sector information: Adjusted operating profit
Half year Half year Year to
to to 31 March
30 September 30 September 2017
2017 2016 GBPm
GBPm GBPm
------------------------------ -------------- -------------- ----------
Materials & Characterisation 7.2 4.2 10.9
Research & Discovery 4.2 7.0 13.8
Service & Healthcare 7.4 5.2 13.3
Total 18.8 16.4 38.0
------------------------------ -------------- -------------- ----------
1. Income statement
The Group's income statement is summarised below.
Table 3: Income statement
Half year Half year Change
to to
30 September 30 September
2017 2016
GBPm GBPm
--------------------------------------------- -------------- -------------- --------
Revenue 132.1 132.4 (0.2%)
--------------------------------------------- -------------- -------------- --------
Adjusted gross profit 67.7 69.5 (2.6%)
Administrative expenses (48.9) (53.1)
--------------------------------------------- -------------- -------------- --------
Adjusted operating profit from
continuing operations 18.8 16.4 +14.6%
Net finance costs (2.5) (3.3)
--------------------------------------------- -------------- -------------- --------
Adjusted profit before tax
from continuing operations 16.3 13.1 +24.4%
Amortisation of acquired intangibles (5.6) (6.0)
Impairment of capitalised development
costs - (0.7)
Non-recurring items and acquisition-related
costs (0.6) (0.6)
Mark-to-market of currency
hedges 2.6 (6.4)
--------------------------------------------- -------------- -------------- --------
Profit/(loss) before tax from
continuing operations 12.7 (0.6)
Tax from continuing operations (2.7) 0.1
--------------------------------------------- -------------- -------------- --------
Profit/(loss) for the period
from continuing operations 10.0 (0.5)
--------------------------------------------- -------------- -------------- --------
Adjusted effective tax rate(1) 22.1% 21.4%
Continuing adj. earnings per
share - basic 22.3p 18.0p +23.9%
Earnings per share - basic 17.5p (0.9p)
Continuing adj. earnings per
share - diluted 22.1p 18.0p +22.8%
Earnings per share - diluted 17.4p (0.9p)
Dividend per share 3.70p 3.70p
--------------------------------------------- -------------- -------------- --------
(1) The adjusted effective tax rate is calculated excluding impairment of non-current assets, amortisation on acquired intangibles, non-recurring items and acquisition related costs and the mark-to-market of financial derivatives
1.1 Revenue
Reported revenue of GBP132.1 million (2016: GBP132.4 million) was broadly flat year-on-year. Materials & Characterisation grew by 10.6% and Service & Healthcare by 7.6%. Research & Discovery declined by 13.4%.
The depreciation of Sterling against the US Dollar, Euro and Japanese Yen has increased reported revenue by GBP5.7 million. Excluding currency effects, revenue grew by 6.6% for Materials & Characterisation with growth across all constituent businesses. Lower optical microscopy sales and an increase in the proportion of customised magnetic and cryogenic systems with longer production lead times, resulted in a constant currency decline of 17.5% in Research & Discovery revenue. Good growth in revenue from service of our own products more than offset a decline in Healthcare revenue, leading to constant currency revenue growth of 2.5% in Service & Healthcare.
On a geographical basis, at constant currency, revenue grew by 4.6% in Europe. Revenue in North America, Asia and Rest of World declined by 10.0%, 1.6% and 64.3% respectively. Orders, at constant currency, increased by 5.5% in Europe, 9.0% in Asia and 333.3% for the Rest of World. Excluding the decline in orders from used imaging systems in the US, orders in North America increased by 5.7%.
1.2 Gross profit
Gross profit fell by 2.6% to GBP67.7 million (2016: GBP69.5 million), representing an adjusted gross profit margin of 51.2%, a decline of 130 basis points over last year.
1.3 Operating profit
Adjusted operating profit increased by 14.6% to GBP18.8 million (2016: GBP16.4 million), representing an adjusted operating profit margin of 14.2%, an increase of 180 basis points against last year. The Materials & Characterisation margin rose by 510 basis points to 14.4% (2016: 9.3%). The revenue decline within Research & Discovery contributed to a fall in adjusted operating margin of 380 basis points to 8.8% (2016: 12.6%). Service & Healthcare margin rose by 530 basis points to 21.7% (2016: 16.4%).
Our share of the ScientaOmicron joint venture showed a breakeven result in the period, an improvement of GBP0.4 million against the comparative period. After restructuring costs, our share of the ScientaOmicron joint venture was a loss of GBP0.3 million.
Currency effects (including the impact of transactional currency hedging) have increased reported adjusted operating profit by GBP4.4 million when compared to blended hedged exchange rates for the comparative period. Blended hedged exchange rates for the US Dollar, Euro and Japanese Yen against Sterling are all at stronger rates than last year.
At constant currency the adjusted operating profit margin was 11.4%, a decline of 100 basis points.
1.4 Adjusting items
Amortisation of acquired intangibles of GBP5.6 million relates to intangible assets identified on acquisitions, being the value of technology, customer relationships and brands.
Non-recurring costs during the period were GBP0.6 million. These comprise GBP0.3 million of restructuring costs relating to our US Healthcare and Asylum businesses and GBP0.3 million of restructuring and charges relating to the ScientaOmicron joint venture.
The Group uses derivative products to hedge its exposure to fluctuations in foreign exchange rates. It is Group policy to have in place at the beginning of the financial year hedging instruments to cover 75% of its forecast transactional exposure for that year. The Group has decided that the additional costs of meeting the extensive documentation requirements of IAS 39 to apply hedge accounting to these foreign exchange hedges cannot be justified. Accordingly, the Group does not use hedge accounting for these derivatives.
Net movements on marking-to-market derivatives in respect of future periods are disclosed in the Income Statement as financial expenditure and excluded from our calculation of adjusted profit before tax.
The mark-to-market gain in respect of derivative financial instruments was GBP2.6 million (2016: GBP6.4 million loss). This reflects a movement from a net fair value liability to a small net asset position on currency derivatives that are hedging future transactional currency exposures for the Group compared to the previous year end. The un-crystallised balance sheet asset is attributable to a rise in the value of Sterling at the balance sheet date against a blended rate achieved on US Dollar, Euro and Japanese Yen forward contracts that will mature over the next eighteen months.
1.5 Net finance costs
The Group's adjusted net finance costs fell by GBP0.8 million to GBP2.5 million (2016: GBP3.3 million) with net finance charges falling by GBP0.5 million to GBP2.2 million and pension financing charges falling by GBP0.3 million to GBP0.3 million.
1.6 Profit before tax
Continuing adjusted profit before tax increased by 24.4% to GBP16.3 million (2016: GBP13.1 million). The continuing adjusted profit before tax margin increased by 240 basis points to 12.3% (2016: 9.9%).
Profit before tax of GBP12.7 million (2016: loss of GBP0.6 million) is after the mark-to-market movement on derivative financial instruments and amortisation of acquired intangibles and other adjusting items.
1.7 Tax
The adjusted tax charge from continuing operations of GBP3.6 million (2016: GBP2.8 million) represents an effective tax rate of 22.1% (2016: 21.4%). The increase is due to a change in the geographical mix of profits. The statutory effective tax rate from continuing operations is 21.3%.
1.8 Earnings per share
Continuing adjusted basic earnings per share increased by 23.9% to 22.3 pence (2016: 18.0 pence); adjusted diluted earnings per share increased by 22.8% to 22.1 pence (2016: 18.0 pence). Continuing adjusted diluted earnings per share were 17.5 pence (2016: loss of 0.9 pence); adjusted diluted earnings per share were 17.4 pence (2016: loss of 0.9 pence).
Undiluted weighted average shares have stayed flat at 57.1 million.
1.9 Foreign Exchange
The Group faces transactional and translational currency exposure, most notably against the US Dollar, Euro and Japanese Yen. For the half year, approximately 16% of Group revenue was denominated in Sterling, 56% in US Dollars, 17% in Euros, 10% in Japanese Yen and 1% in other currencies. Translational exposures arise on the consolidation of overseas company results into Sterling. Transactional exposures arise where the currency of sale or purchase transactions differs from the functional currency in which each company prepares its local accounts.
The Group maintains a hedging programme against its net transactional exposure using internal projections of currency trading transactions expected to arise over a period extending from 12 to 24 months. As at 30 September 2017 the Group had currency hedges in place extending up to 18 months forward.
2. Dividend
The Group's policy is to increase the dividend each year in line with the increase in underlying earnings. However, taking into account the impact on the Group of business disposals, currency effects and our progressive strengthening of the balance sheet, the Board has proposed to hold the dividend at last year's level. This results in an interim dividend of 3.7 pence. The dividend will be paid on 6 April 2018 to shareholders on the register as at 23 February 2018.
3. Cash flow
The Group cash flow is summarised below. Adjusted operating cash flow excludes rental assets held for resale and profits or losses on disposal of fixed assets, both of which are included within expenditure on tangible and intangible assets.
Table 4: Cash flow from continuing operations
Half year to Half year
30 September to
2017 30 September
GBPm 2016
GBPm
------------------------------------------- -------------- --------------
Adjusted operating profit 18.8 16.4
Depreciation and amortisation 4.0 4.0
------------------------------------------- -------------- --------------
Adjusted EBITDA 22.8 20.4
Working capital movement (15.0) (14.9)
Non-recurring items and acquisition
related costs (0.7) (0.4)
Pension scheme payments above charge
to op. profit (3.5) (3.5)
Equity settled share schemes 0.5 -
Share of loss of associate - 0.4
Adjusted operating cash flow 4.1 2.0
Interest (1.0) (2.6)
Tax (2.5) (0.7)
Expenditure on tangible and intangible
assets (2.8) (1.9)
Capitalised development expenditure (3.1) (3.0)
Increase in investment in associate (2.1) -
Acquisition of subsidiaries, net of
cash acquired - (6.8)
Net cash flow from sale of subsidiary 73.0 -
undertaking
Dividends paid (2.1) (2.1)
Proceeds from issue of share capital 0.2 -
(Decrease)/increase in borrowings (77.6) 11.6
------------------------------------------- -------------- --------------
Net decrease in cash and cash equivalents
from continuing operations (13.9) (3.5)
------------------------------------------- -------------- --------------
Note: Adjusted EBITDA is earnings before interest, tax, depreciation, intangible amortisation, mark-to-market of financial derivatives and other non-cash adjusting items
3.1 Adjusted operating cash flow
Adjusted operating cash flow in the year increased by GBP2.1 million to GBP4.1 million (2016: GBP2.0 million). Adjusted operating cash (defined as adjusted EBITDA, less movement in working capital, capitalised development expenditure and capital expenditure) represents 10.1% (2016: 3.7%) of adjusted operating profit due to an outflow of working capital over the period.
The working capital outflow of GBP15.0 million reflects an increase in inventories of GBP6.6 million, an increase in receivables of GBP1.3 million, a decrease in payables of GBP9.2 million and an increase in customer deposits of GBP2.1 million. The increase in inventories largely reflects an increase in work in progress and inventory of customised magnets and cryogenic systems. The fall in payables is due to inventory building during the last quarter of last year to support order growth of our Plasma Technology process tools, combined with the cash settlement of currency hedging contracts.
3.2 Interest
Net interest paid was GBP1.0 million (2016: GBP2.6 million). The difference from last year is due to lower financing costs arising from a lower level of average net debt compared to the comparative period following the receipt of proceeds from the sale of Industrial Analysis part way through the period and the settlement of GBP1.0 million of interest payments made just after the half year close.
3.3 Tax
Tax paid was GBP2.5 million (2016: GBP0.7 million), the comparative period benefiting from tax deductions on allowable adjusting items and utilisation of brought forward tax losses.
3.4 Investment in research and development (R&D)
Total cash spend on R&D in the half year was GBP13.0 million, equivalent to 9.8% of sales, (2016: 13.0 million, 9.8% of sales). A reconciliation between the amounts charged to the Income Statement and the cash spent is given below:
Table 5: Investment in research and development (R&D) from continuing operations
Half year Half year
to to
30 September 30 September
2017 2016
GBPm GBPm
---------------------------------------------- -------------- --------------
R&D expense charged to the Income Statement 11.4 12.1
Amounts capitalised as fixed assets 0.1 0.1
Amortisation and impairment of R&D
costs capitalised as intangibles (1.6) (2.2)
Amounts capitalised as intangible assets 3.1 3.0
---------------------------------------------- -------------- --------------
Total cash spent on R&D during the
year 13.0 13.0
---------------------------------------------- -------------- --------------
3.5 Investment in Associate
The shareholders of ScientaOmicron agreed to a capital injection to strengthen the balance sheet of the joint venture and ensure future liquidity in support of the business strategy. Our share was GBP2.1 million and was paid in September 2017.
3.6 Disposals
The sale of Industrial Analysis was completed on 3 July 2017. A post-tax profit of GBP45.3 million has been recorded within discontinued adjusting items this includes an impairment of GBP1.8 million of capitalised development costs.
4 Net debt and funding 4.1 Net debt
Net debt decreased in the period from GBP109.3 million to GBP45.5 million. Operating cash flow was GBP4.1 million. Disposal proceeds of GBP73.0 million relate to the sale of Industrial Analysis. The Group invested in tangible and intangible assets of GBP2.8 million and capitalised development costs of GBP3.1 million.
Table 6: Movement in net debt
GBPm
--------------------------------------------------- -------
Net debt as at 31 March 2017 109.3
Adjusted operating cash flow (4.1)
Interest 2.0
Tax 2.5
Capital expenditure on tangible and intangible
assets 2.8
Capitalised development expenditure 3.1
Increase in investment in associate 2.1
Net cash flow from sale of subsidiary undertaking (73.0)
Dividends paid 2.1
Other items (1.3)
--------------------------------------------------- -------
Net debt as at 30 September 2017 45.5
--------------------------------------------------- -------
4.2 Funding
The Group has in place an unsecured multi-currency revolving facility agreement which is committed until February 2020. The facility has been entered into with a group of three banks and comprises a Sterling denominated multi-currency facility of GBP100.0 million and a US Dollar denominated multi-currency facility of $37.0 million.
In this half year the Group has repaid GBP5.0 million of its bilateral private placement note, leaving an outstanding note of GBP39.5 million, which matures in 2021. In September 2017, the Group repaid the balance of its amortising fixed rate loan from the European Investment Bank. The Group has uncommitted facilities of GBP20.6 million.
Debt covenants are net debt to EBITDA less than 3.0 times and EBITDA to interest greater than 4.0 times. As at 30 September 2017 net debt to EBITDA was at 0.9 times and EBITDA to interest was 10.1 times, both well within our banking covenants.
5 Pensions
The Group has defined benefit pension schemes in the UK and USA. Both have been closed to new entrants since 2001 and closed to future accrual from July 2010.
At 30 September 2017, the net liability arising from our defined benefit scheme obligations was GBP22.5 million (31 March 2017: GBP25.1 million), a fall of GBP2.6 million. The reduction in the deficit was primarily due to the contributions paid in the period. Total scheme assets at 30 September 2017 were GBP283.3 million (31 March 2017: GBP287.9 million) while liabilities were GBP305.8 million (2016: GBP313.0 million).
6 Going Concern
The Group's business activities, together with the factors likely to affect its future development, performance and position, are set out in the Performance, Strategy and Operations sections. The financial position of the Group, its cash flows, liquidity position and borrowing facilities are described in the Financial Review.
The diverse nature of the Group, combined with its financial strength, provides a solid foundation for a sustainable business. The Directors have reviewed the Group's forecasts and flexed them to incorporate a number of potential scenarios relating to changes in trading performance. The Directors believe that the Group will be able to operate within its existing debt facilities. This review also considered hedging arrangements in place. The Directors believe that the Group is well placed to manage its business risks successfully.
The Financial Statements have been prepared on a going concern basis, based on the Directors' opinion, after making reasonable enquires, that the Group has adequate resources to continue in operational existence for the foreseeable future.
7 Forward-Looking Statements
This document contains certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involving a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.
Gavin Hill
Group Finance Director
14 November 2017
Condensed Consolidated Statement of Income
Half year ended 30 September 2017 - unaudited
Half Year to 30 Sept Half Year to 30 Sept
2017 2016
Adjusted Adjusting Total Adjusted Adjusting Total
items* items*
Notes GBPm GBPm GBPm GBPm GBPm GBPm
-------------------------------- ------ --------- ---------- ------- --------- ---------- -------
Revenue 3 132.1 - 132.1 132.4 - 132.4
Cost of sales (64.4) - (64.4) (62.9) - (62.9)
-------------------------------- ------ --------- ---------- ------- --------- ---------- -------
Gross profit 67.7 - 67.7 69.5 - 69.5
Research and development 4 (11.4) - (11.4) (11.4) (0.7) (12.1)
Selling and marketing (25.4) - (25.4) (25.3) - (25.3)
Administration and
shared services (11.9) (5.9) (17.8) (12.5) (6.3) (18.8)
Share of loss of associate,
net of tax - (0.3) (0.3) (0.4) (0.1) (0.5)
Foreign exchange loss (0.2) - (0.2) (3.5) - (3.5)
-------------------------------- ------ --------- ---------- ------- --------- ---------- -------
Operating profit/(loss) 18.8 (6.2) 12.6 16.4 (7.1) 9.3
Other financial income 0.1 2.6 2.7 0.1 - 0.1
-------------------------------- ------ --------- ---------- ------- --------- ---------- -------
Financial income 0.1 2.6 2.7 0.1 - 0.1
Interest charge on
pension scheme net (0.3) - (0.3) (0.6) - (0.6)
liabilities
Other financial expenditure (2.3) - (2.3) (2.8) (6.6) (9.4)
Financial expenditure (2.6) - (2.6) (3.4) (6.6) (10.0)
Profit/(loss) before
income tax from continuing
operations 3 16.3 (3.6) 12.7 13.1 (13.7) (0.6)
Income tax (expense)/credit 7 (3.6) 0.9 (2.7) (2.8) 2.9 0.1
-------------------------------- ------ --------- ---------- ------- --------- ---------- -------
Profit/(loss) for
the period from continuing
operations 12.7 (2.7) 10.0 10.3 (10.8) (0.5)
-------------------------------- ------ --------- ---------- ------- --------- ---------- -------
Profit/(loss) from
discontinued operations
after tax 6 0.3 45.3 45.6 1.9 (2.1) (0.2)
Profit/(loss) for
the period attributable
to equity holders
of the parent 13.0 42.6 55.6 12.2 (12.9) (0.7)
-------------------------------- ------ --------- ---------- ------- --------- ---------- -------
pence pence pence pence
-------------------------------- ------ --------- ---------- ------- --------- ---------- -------
Earnings per share
Basic earnings per
share 8
From continuing operations 22.3 17.5 18.0 (0.9)
From discontinued
operations 6 0.5 79.9 3.4 (0.4)
-------------------------------- ------ --------- ---------- ------- --------- ---------- -------
From profit/(loss)
for the period 22.8 97.4 21.4 (1.3)
Diluted earnings per
share 8
From continuing operations 22.1 17.4 18.0 (0.9)
From discontinued
operations 6 0.5 79.5 3.3 (0.4)
-------------------------------- ------ --------- ---------- ------- --------- ---------- -------
From profit/(loss)
for the period 22.6 96.9 21.3 (1.3)
Dividends per share
Dividends paid 9 3.70 3.70
Dividends proposed 9 3.70 3.70
-------------------------------- ------ --------- ---------- ------- --------- ---------- -------
* Adjusted numbers are stated to give a better understanding of the underlying business performance. Details of adjusting items can be found in note 2 of this Half Year Report.
Condensed Consolidated Statement of Income
Half year ended 30 September 2017 - unaudited
Year to 31 March 2017
Adjusted Adjusting Total
items*
Notes GBPm GBPm GBPm
------------------------------------- ------ --------- ---------- --------
Revenue 3 300.2 - 300.2
Cost of sales (142.9) - (142.9)
------------------------------------------ ------ --------- ---------- --------
Gross profit 157.3 - 157.3
Research and development 4 (23.6) (0.7) (24.3)
Selling and marketing (54.1) - (54.1)
Administration and shared services (28.8) (49.6) (78.4)
Share of loss of associate,
net of tax (0.8) (8.4) (9.2)
Foreign exchange loss (12.0) - (12.0)
------------------------------------------ ------ --------- ---------- --------
Operating profit/(loss) 38.0 (58.7) (20.7)
------------------------------------------
Other financial income 0.2 1.2 1.4
------------------------------------------ ------ --------- ---------- --------
Financial income 0.2 1.2 1.4
Interest charge on pension
scheme net liabilities (1.1) - (1.1)
Other financial expenditure (5.6) (0.2) (5.8)
--------
Financial expenditure (6.7) (0.2) (6.9)
Profit/(loss) before income
tax from continuing operations 3 31.5 (57.7) (26.2)
Income tax (expense)/credit 7 (7.8) 8.5 0.7
------------------------------------------ ------ --------- ---------- --------
Profit/(loss) for the year
from continuing operations 23.7 (49.2) (25.5)
------------------------------------------ ------ --------- ---------- --------
Profit from discontinued operations
after tax 6 4.3 0.9 5.2
Profit/(loss) for the year
attributable to equity holders
of the parent 28.0 (48.3) (20.3)
------------------------------------------ ------ --------- ---------- --------
Earnings per share
Basic earnings per share 8
From continuing operations 41.5 (44.7)
From discontinued operations 7.5 9.1
------------------------------------------ ------ --------- ---------- --------
From profit/(loss) for the
period 49.0 (35.6)
Diluted earnings per share 8
From continuing operations 41.4 (44.7)
From discontinued operations 7.5 9.1
------------------------------------------ ------ --------- ---------- --------
From profit/(loss) for the
period 48.9 (35.6)
Dividends per share
Dividends paid 9 13.0
Dividends proposed 9 13.0
------------------------------------------ ------ --------- ---------- --------
*Adjusted numbers are stated to give a better understanding of the underlying business performance. Details of adjusting items can be found in note 2 of this Half Year Report.
Condensed Consolidated Statement of Comprehensive Income
Half year ended 30 September 2017 - unaudited
Half year Half year Year to
to to
30 Sept 30 Sept 31 March
2017 2016 2017
GBPm GBPm GBPm
-------------------------------------------------- ---------- ---------- ---------
Profit/(loss) for the period 55.6 (0.7) (20.3)
Other comprehensive income/(expense):
Items that may be reclassified subsequently
to profit or loss
Gain/(loss) on effective portion of changes
in fair value of cash flow hedges, net
of amounts recycled - 0.1 0.1
Foreign exchange translation differences (5.4) 14.7 18.8
Net cumulative foreign exchange gain
on disposal of subsidiaries recycled
to the Income Statement (4.8) - (5.7)
Tax on items that may be reclassified
to profit or loss - - -
Items that will not be reclassified subsequently
to profit or loss
Remeasurement (loss)/gain in respect
of post retirement benefits (0.8) (15.1) 4.4
Tax on items that will not be reclassified
to profit or loss 0.2 2.7 (0.9)
-------------------------------------------------- ---------- ---------- ---------
Total other comprehensive income (10.8) 2.4 16.7 Total comprehensive income for the period attributable to equity shareholders of the parent 44.8 1.7 (3.6) -------------------------------------------------- ---------- ---------- ---------
Condensed Consolidated Statement of Changes in Equity
Half year ended 30 September 2017 - unaudited
Foreign
Share exchange
Share premium Other translation Retained
capital account reserves reserve earnings Total
GBPm GBPm GBPm GBPm GBPm GBPm
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Balance at 1 April 2017 2.9 61.5 0.2 22.8 45.1 132.5
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Total comprehensive income:
Profit for the period - - - - 55.6 55.6
Other comprehensive income:
* Foreign exchange translation differences - - - (5.4) - (5.4)
* Net foreign exchange gain on disposal of subsidiaries
recycled to the Income Statement - - - (4.8) - (4.8)
* Remeasurement loss in respect of post-retirement
benefits - - - - (0.8) (0.8)
* Tax on items recognised directly in other
comprehensive income - - - - 0.2 0.2
------------------------------------------------------------
Total comprehensive (expense)/income
attributable to equity shareholders
of the parent - - - (10.2) 55.0 44.8
Transactions with owners recorded
directly in equity:
* Proceeds from issue of shares - 0.2 - - - 0.2
* Credit in respect of employee service costs settled
by award of share options - - - - 0.5 0.5
* Dividends payable - - - - (7.4) (7.4)
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Total transactions with owners recorded
directly in equity: - 0.2 - - (6.9) (6.7)
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Balance at 30 September 2017 2.9 61.7 0.2 12.6 93.2 170.6
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Foreign
Share exchange
Share premium Other translation Retained
capital account reserves reserve earnings Total
GBPm GBPm GBPm GBPm GBPm GBPm
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Balance at 1 April 2016 2.9 61.5 0.1 9.7 68.8 143.0
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Total comprehensive income:
Loss for the period - - - - (0.7) (0.7)
Other comprehensive income:
* Foreign exchange translation differences - - - 14.7 - 14.7
* Gain on effective portion of changes in fair value of
cash flow hedges, net of amounts recycled - - 0.1 - - 0.1
* Remeasurement loss in respect of post-retirement
benefits - - - - (15.1) (15.1)
* Tax on items recognised directly in other
comprehensive income - - - - 2.7 2.7
------------------------------------------------------------
Total comprehensive income/(expense)
attributable to equity shareholders
of the parent - - 0.1 14.7 (13.1) 1.7
Transactions with owners recorded
directly in equity:
* Dividends payable - - - - (7.4) (7.4)
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Total transactions with owners recorded
directly in equity: - - - - (7.4) (7.4)
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Balance at 30 September 2016 2.9 61.5 0.2 24.4 48.3 137.3
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Condensed Consolidated Statement of Changes in Equity
Half year ended 30 September 2017 - unaudited continued
Foreign
Share exchange
Share premium Other translation Retained
capital account reserves reserve earnings Total
GBPm GBPm GBPm GBPm GBPm GBPm
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Balance at 1 April 2016 2.9 61.5 0.1 9.7 68.8 143.0
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Total comprehensive income:
Loss for the year - - - - (20.3) (20.3)
Other comprehensive income:
* Foreign exchange translation differences - - - 18.8 - 18.8
* Net foreign exchange gain on disposal of subsidiaries
taken to the Income Statement - - - (5.7) - (5.7)
* Gain on effective portion of changes in fair value of
cash flow hedges, net of amounts recycled - - 0.1 - - 0.1
* Remeasurement gain in respect of post-retirement
benefits - - - - 4.4 4.4
* Tax on items recognised directly in other
comprehensive income - - - - (0.9) (0.9)
------------------------------------------------------------
Total comprehensive (expense)/income
attributable to equity shareholders
of the parent - - 0.1 13.1 (16.8) (3.6)
Transactions with owners recorded
directly in equity:
* Charge in respect of employee service costs settled
by award of share options - - - - 0.5 0.5
* Dividends payable - - - - (7.4) (7.4)
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Total transactions with owners
recorded directly in equity: - - - - (6.9) (6.9)
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Balance at 31 March 2017 2.9 61.5 0.2 22.8 45.1 132.5
------------------------------------------------------------ ------- ------- -------- ----------- -------- ------
Condensed Consolidated Statement of Financial Position
As at 30 September 2017 - unaudited
As at As at As at
30 Sept 30 Sept 31 March
2017 2016 2017
GBPm GBPm GBPm
Assets
Non-current assets
Property, plant and equipment 29.3 36.0 32.5
Intangible assets 164.9 220.7 181.0
Investment in associate 5.7 12.6 3.9
Long-term receivables 2.1 3.6 3.6
Deferred tax assets 28.8 21.5 26.0
230.8 294.4 247.0
Current assets
Inventories 48.6 69.8 53.9
Trade and other receivables 67.8 79.2 81.1
Current income tax receivable 3.9 2.4 4.2
Derivative financial instruments 2.3 - 0.6
Cash and cash equivalents 14.3 20.9 27.2
136.9 172.3 167.0
Total assets 367.7 466.7 414.0
---------------------------------------- -------- -------- ---------
Equity
Capital and reserves attributable
to the Company's equity shareholders
Share capital 2.9 2.9 2.9
Share premium 61.7 61.5 61.5
Other reserves 0.2 0.2 0.2
Translation reserve 12.6 24.4 22.8
Retained earnings 93.2 48.3 45.1
170.6 137.3 132.5
Liabilities
Non-current liabilities
Bank loans 59.2 154.0 129.6
Retirement benefit obligations 22.5 47.5 25.1
Deferred tax liabilities 10.3 1.8 5.6
---------------------------------------- -------- -------- ---------
92.0 203.3 160.3
Current liabilities
Bank loans and overdrafts 0.6 8.0 6.9
Trade and other payables 79.0 87.3 93.0
Current income tax payables 9.3 3.5 6.5
Accrued dividend 5.3 5.3 -
Derivative financial instruments 1.0 10.9 5.0
Provisions 9.9 11.1 9.8
---------------------------------------- -------- -------- ---------
105.1 126.1 121.2
Total liabilities 197.1 329.4 281.5
Total liabilities and equity 367.7 466.7 414.0
---------------------------------------- -------- -------- ---------
Condensed Consolidated Statement of Cash Flows
half year ended 30 September 2017 - unaudited
Half year Half year Year to
to to
30 Sept 30 Sept 31 March
2017 2016 2017
GBPm GBPm GBPm
---------------------------------------------- ---------- ---------- -----------
Profit/(loss) for the period from continuing
operations 10.0 (0.5) (25.5)
Adjustments for:
Income tax expense/(credit) 2.7 (0.1) (0.7)
Net financial (income)/expense (0.1) 9.9 5.5
Acquisition related costs - 0.3 0.3
Restructuring costs 0.3 - 0.4
Restructuring costs - relating to associate 0.3 0.1 0.4
Impairment of capitalised development
costs - 0.7 0.7
Loss on disposal of subsidiary - - 0.4
Impairment of investment in associate - - 8.0
Amortisation and impairment of acquired
intangibles 5.6 6.0 46.3
Impairment of capitalised intangible
software costs - - 2.2
Depreciation of property, plant and
equipment 2.4 2.5 5.1
Amortisation of capitalised development
costs 1.6 1.5 3.8
---------------------------------------------- ---------- ---------- -----------
Adjusted earnings before interest,
tax, depreciation and amortisation 22.8 20.4 46.9
Loss on disposal of plant, property
and equipment 0.2 0.3 0.5
Cost of equity settled employee share
schemes 0.5 - 0.5
Share of loss from associate - 0.4 0.8
Acquisition related costs paid - - -
Restructuring costs paid (0.7) (0.4) (1.1)
Foreign currency loss on intra-Group
Dividends - - (0.8)
Cash payments to the pension scheme
more than the charge to operating profit (3.5) (3.5) (6.9)
---------------------------------------------- ---------- ---------- -----------
Operating cash flows before movements
in working capital 19.3 17.2 39.9
Increase in inventories (6.6) (3.7) (1.7)
(Increase)/decrease in receivables (1.3) 2.9 (1.1)
Decrease in payables and provisions (9.2) (14.3) (2.5)
Increase in customer deposits 2.1 0.2 0.9
Purchase of rental assets held for
later resale (0.6) (0.5) (1.0)
Cash generated by operations 3.7 1.8 34.5
Interest paid (1.0) (2.6) (5.0)
Income taxes paid (2.5) (0.7) (2.1)
---------------------------------------------- ---------- ---------- -----------
Net cash from operating activities 0.2 (1.5) 27.4
---------------------------------------------- ---------- ---------- -----------
Cash flows from investing activities
Acquisition of subsidiaries - net of
cash acquired - (6.8) (9.8)
Acquisition of property, plant and
equipment (2.2) (1.6) (3.0)
Acquisition of intangible assets (0.2) (0.1) (0.1)
Net cash flow on disposal of businesses 73.0 - 12.2
Capitalised development expenditure (3.1) (3.0) (5.9)
Increase in investment in associate (2.1) - -
---------------------------------------------- ---------- ---------- -----------
Net cash generated from/(used in) investing
activities 65.4 (11.5) (6.6)
---------------------------------------------- ---------- ---------- -----------
Cash flows from financing activities
Proceeds from issue of share capital 0.2 - -
(Decrease)/increase in borrowings (77.6) 11.6 (12.8)
Dividends paid (2.1) (2.1) (7.4)
---------------------------------------------- ---------- ---------- -----------
Net cash (used in)/generated from financing
activities (79.5) 9.5 (20.2)
---------------------------------------------- ---------- ---------- -----------
Net decrease in cash and cash equivalents
from continuing operations (13.9) (3.5) 0.6
Increase in cash from discontinued
operations 1.9 0.6 3.6
Cash and cash equivalents at beginning
of the period 26.5 20.4 20.4
Effect of exchange rate fluctuations
on cash held (0.8) 1.6 1.9
---------------------------------------------- ---------- ---------- -----------
Cash and cash equivalents at end of
the period 13.7 19.1 26.5
---------------------------------------------- ---------- ---------- -----------
Reconciliation of changes in cash and cash equivalents to movement
in net debt
Half year Half year Year to
to to
30 Sept 30 Sept 31 March
2017 2016 2017
GBPm GBPm GBPm
---------------------------------------------- ---------- ---------- ---------
(Decrease)/increase in cash and cash
equivalents (12.0) (2.9) 4.2
Effect of foreign exchange rate changes
on cash and cash equivalents (0.8) 1.6 1.9
---------------------------------------------- ---------- ---------- ---------
(12.8) (1.3) 6.1
Cash outflow/(inflow) from decrease/increase
in debt 77.6 (11.6) 12.8
Accrued interest (1.0) - -
Movement in net debt in the period 63.8 (12.9) 18.9
Net debt at start of the period (109.3) (128.2) (128.2)
---------------------------------------------- ---------- ---------- ---------
Net debt at the end of the period (45.5) (141.1) (109.3)
---------------------------------------------- ---------- ---------- ---------
Notes on the Half Year Financial Statements
Half year ended 30 September 2017 - unaudited
1 BASIS OF PREparATION OF ACCOUNTS
Reporting entity
Oxford Instruments plc is a company incorporated in England and Wales. The condensed consolidated half year financial statements consolidate the results of the Company and its subsidiaries (together referred to as the Group). They have been prepared and approved by the Directors in accordance with International Financial Reporting Standard (IFRS) IAS 34 Interim Financial Reporting as adopted by the EU. They do not include all of the information required for full annual financial statements, and should be read in conjunction with the consolidated financial statements of the Group for the year ended 31 March 2017.
The financial information contained herein is unaudited and does not constitute statutory accounts as defined by Section 435 of the Companies Act 2006. The comparative figures for the financial year ended 31 March 2017 are not the company's statutory accounts for that financial year. Those accounts have been reported on by the Company's auditors and delivered to the registrar of companies. The report of the auditors was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498 (2) or (3) of the Companies Act 2006.
Significant accounting policies
As required by the Disclosure and Transparency Rules of the Financial Conduct Authority, the condensed set of financial statements has been prepared applying the accounting policies and presentation that were applied in the preparation of the Company's published consolidated financial statements for the year ended 31 March 2017, except as explained below.
Adoption of new and revised standards
At present, there are no other new standards, amendments to standards or interpretations mandatory for the first time for the year ending 31 March 2018.
Estimates
The preparation of half year financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.
In preparing these half year financial statements, the significant judgements made by management in applying the group's accounting policies and key sources of estimation uncertainty were the same as those that applied to the Consolidated Financial Statements as at and for the year ended 31 March 2017.
Going concern
The condensed consolidated half year financial statements have been prepared on a going concern basis, based on the Directors' opinion, after making reasonable enquiries, that the Group has adequate resources to continue in operational existence for the foreseeable future.
Notes on the Half Year Financial Statements (continued)
Half year ended 30 September 2017 - unaudited
1 BASIS OF PREparATION OF ACCOUNTS continued
Exchange rates
The principal exchange rates used to translate the Group's overseas results were as follows:
Half year Half year
Period end rates to to Year to
30 Sept 30 Sept 31 March
2017 2016 2017
US Dollar 1.34 1.30 1.25
Euro 1.13 1.16 1.17
Yen 151 132 139
-------------------------------- ---------- ---------- ---------
Average translation rates US Dollar Euro Yen
-------------------------------- ---------- ---------- ---------
Half year to 30 September 2017
April 1.27 1.18 142
May 1.29 1.17 143
June 1.29 1.14 144
July 1.31 1.13 146
August 1.30 1.10 143
September 1.31 1.11 146
-------------------------------- ---------- ---------- ---------
Average translation rates year ended
31 March 2017 US Dollar Euro Yen
April 1.45 1.27 159
May 1.46 1.30 159
June 1.41 1.27 150
July 1.35 1.21 138
August 1.32 1.18 134
September 1.31 1.16 132
October 1.26 1.13 130
November 1.23 1.14 134
December 1.24 1.17 142
January 1.25 1.17 144
February 1.25 1.18 142
March 1.25 1.18 140
-------------------------------------- ---------- ----- ----
Notes on the Half Year Financial Statements (continued)
Half year ended 30 September 2017 - unaudited
2 NON-GAAP MEASURES
The Directors present the following non-GAAP measures as they believe it gives a better indication of the underlying performance of the business.
Reconciliation between operating profit and profit before income tax and adjusted profit from continuing operations
Profit/(loss)
before income
Operating profit/(loss) tax
Half Half Half Half
year year Year year year Year
to to to to to to
30 30 31 30 30 31
Sep Sep Mar Sep Sep Mar
2017 2016 2017 2017 2016 2017
GBPm GBPm GBPm GBPm GBPm GBPm
---------------------------------------------- -------- -------- -------- ------ ------ -------
Statutory measure from continuing operations 12.6 9.3 (20.7) 12.7 (0.6) (26.2)
Acquisition related costs - 0.3 0.3 - 0.3 0.3
Restructuring costs 0.3 - 0.4 0.3 - 0.4
Restructuring costs - relating to associate 0.3 0.1 0.4 0.3 0.1 0.4
Loss on disposal of subsidiary - - 0.4 - - 0.4
Unwind of discount in respect of contingent
consideration and acquisition related
accruals - - - - 0.2 0.2
---------------------------------------------- -------- -------- -------- ------ ------ -------
Non-recurring and acquisition related
items 0.6 0.4 1.5 0.6 0.6 1.7
Impairment of acquired intangibles - - 33.8 - - 33.8
Impairment of investment in associate - - 8.0 - - 8.0
Impairment of capitalised development
costs - 0.7 0.7 - 0.7 0.7
Impairment of capitalised software costs - - 2.2 - - 2.2
Amortisation of acquired intangibles 5.6 6.0 12.5 5.6 6.0 12.5
Mark-to-market (gain)/loss in respect
of derivative financial instruments - - - (2.6) 6.4 (1.2)
---------------------------------------------- -------- -------- -------- ------ ------ -------
Adjusted measure from continuing operations 18.8 16.4 38.0 16.3 13.1 31.5
Share of taxation - - - (3.6) (2.8) (7.8)
---------------------------------------------- -------- -------- -------- ------ ------ -------
Adjusted profit for the period from
continuing operations 18.8 16.4 38.0 12.7 10.3 23.7
---------------------------------------------- -------- -------- -------- ------ ------ -------
Acquisition related costs comprise professional fees incurred in relation to mergers and acquisitions activity and any consideration which, under IFRS 3 (revised), falls to be treated as a post-acquisition employment expense.
Restructuring costs comprise one-off costs in respect of cost reduction programmes in the US Healthcare and Asylum businesses. Restructuring costs relating to the Group's associate relate to exceptional costs incurred by the associate arising from the merger of the Scienta and Omicron businesses.
In order to assist with comparability between peers, adjusted profit excludes the non-cash amortisation and impairment of acquired intangible assets and goodwill and the unwind of discounts in respect of contingent consideration relating to business combinations.
The Group reports ineffectiveness of its hedging as an adjusting item. In the prior year, this included losses on certain contracts relating to the hedging of the Japanese Yen which were not required for ordinary trading and which were re-allocated for use against the remittance of net income of the Group's Japan operations. Additionally, under IAS 39, all derivative financial instruments are recognised initially at fair value. Subsequent to initial recognition, they are also measured at fair value. In respect of instruments used to hedge foreign exchange risk and interest rate risk the Group does not take advantage of the hedge accounting rules provided for in IAS 39 since that standard requires certain stringent criteria to be met in order to hedge account, which, in the particular circumstances of the Group, are considered by the Board not to bring any significant economic benefit. Accordingly, the Group accounts for these derivative financial instruments at fair value through profit or loss. To the extent that instruments are hedges of future transactions, adjusted profit for the year is stated before changes in the valuation of these instruments so that the underlying performance of the Group can be more clearly seen.
Notes on the Half Year Financial Statements (continued)
Half year ended 30 September 2017 - unaudited
2 NON-GAAP MEASURES continued
In the prior year:
-- the Group settled various claims totalling GBP0.4m relating to the disposal of its Omicron business in 2015;
-- the Group recognised an impairment of GBP8.0m relating to its equity accounted associate investment;
-- the one off impairment of capitalised development costs related to a specific internal systems project that was stopped as the Group focused and directed resources so as to accelerate projects; and
-- the one off impairment of capitalised software costs was carried out following a reassessment of the future value expected to be derived from internally developed software.
3 SEGMENT Information
The Group has ten operating segments. These operating segments have been combined into three aggregated operating segments to the extent that they have similar economic characteristics, with relevance to products and services, type and class of customer, methods of sale and distribution and the regulatory environment in which they operate. Each of these three aggregated operating segments is a reportable segment.
The Group's internal management structure and financial reporting systems differentiate the three aggregated operating segments on the basis of the economic characteristics discussed below:
-- the Materials and Characterisation segment comprises a group of businesses focusing on applied R&D and commercial customers, enabling the fabrication and characterisation of materials and devices down to the atomic scale;
-- the Research and Discovery segment comprises a group of businesses providing advanced solutions that create unique environments and enable measurements down to the molecular and atomic level which are used in fundamental research; and
-- the Service and Healthcare segment provides customer service and support for the Group's products and the service, sale and rental of third party healthcare imaging systems.
Reportable segment results include items directly attributable to a segment as well as those which can be allocated on a reasonable basis. Inter-segment pricing is determined on an arm's length basis. The operating results of each are regularly reviewed by the Chief Operating Decision Maker, which is deemed to be the Board of Directors. Discrete financial information is available for each segment and used by the Board of Directors for decisions on resource allocation and to assess performance. No asset information is presented below as this information is not presented in reporting to the Group's Board of Directors.
Results from continuing operations
Half year to 30 September 2017
Materials Research Service &
& &
Characterisation Discovery Healthcare Total
GBPm GBPm GBPm GBPm
---------------------------- ---------------- --------- ---------- -----
External revenue 50.1 47.9 34.1 132.1
Inter-segment revenue - 0.1 -
---------------------------- ---------------- --------- ----------
Total segment revenue 50.1 48.0 34.1
Segment operating profit
from continuing operations 7.2 4.2 7.4 18.8
---------------------------- ---------------- --------- ---------- -----
Results from continuing operations
Half year to 30 September 2016
Materials Research Service &
& &
Characterisation Discovery Healthcare Total
GBPm GBPm GBPm GBPm
---------------------------- ---------------- --------- ---------- -----
External revenue 45.3 55.4 31.7 132.4
Inter-segment revenue - - -
---------------------------- ---------------- --------- ----------
Total segment revenue 45.3 55.4 31.7
Segment operating profit
from continuing operations 4.2 7.0 5.2 16.4
---------------------------- ---------------- --------- ---------- -----
Notes on the Half Year Financial Statements (continued)
Half year ended 30 September 2017 - unaudited
3 SEGMENT Information continued
Results from continuing operations
Year to 31 March 2017
Materials Research Service &
& &
Characterisation Discovery Healthcare Total
GBPm GBPm GBPm GBPm
---------------------------- ---------------- --------- ---------- -----
External revenue 104.1 125.2 70.9 300.2
Inter-segment revenue - 0.1 -
---------------------------- ---------------- --------- ----------
Total segment revenue 104.1 125.3 70.9
Segment operating profit
from continuing operations 10.9 13.8 13.3 38.0
---------------------------- ---------------- --------- ---------- -----
The adjusted result after tax of GBPnil (2016/17 half year: GBP0.4m loss; full year: GBP0.8m loss) from the Group's associate is reported within the Research & Discovery segment.
Reconciliation of reportable segment profit
Unallocated
Materials Research Service Group
& Characterisation & Discovery & Healthcare items Total
Half year to 30 September 2017 GBPm GBPm GBPm GBPm GBPm
-------------------------------------- -------------------- ------------- -------------- ------------ ------
Operating profit for reportable
segments from continuing operations 7.2 4.2 7.4 - 18.8
Restructuring costs (0.1) - (0.2) - (0.3)
Restructuring costs - relating
to associate - (0.3) - - (0.3)
Amortisation of acquired intangibles (1.3) (3.8) (0.5) - (5.6)
Financial income - - - 2.7 2.7
Financial expenditure - - - (2.6) (2.6)
-------------------------------------- -------------------- ------------- -------------- ------------ ------
Profit before income tax from
continuing operations 5.8 0.1 6.7 0.1 12.7
-------------------------------------- -------------------- ------------- -------------- ------------ ------
Unallocated
Materials Research Service Group
& Characterisation & Discovery & Healthcare items Total
Half year to 30 September 2016 GBPm GBPm GBPm GBPm GBPm
--------------------------------------- -------------------- ------------- -------------- ------------ -------
Operating profit for reportable
segments from continuing operations 4.2 7.0 5.2 - 16.4
Acquisition related costs - (0.3) - - (0.3)
Restructuring costs - relating
to associate - (0.1) - - (0.1)
Impairment of capitalised development
costs (0.7) - - - (0.7)
Amortisation of acquired intangibles (1.4) (3.7) (0.9) - (6.0)
Financial income - - - 0.1 0.1
Financial expenditure - - - (10.0) (10.0)
--------------------------------------- -------------------- ------------- -------------- ------------ -------
Loss before income tax from
continuing operations 2.1 2.9 4.3 (9.9) (0.6)
--------------------------------------- -------------------- ------------- -------------- ------------ -------
Unallocated
Materials Research Service Group
& Characterisation & Discovery & Healthcare items Total
Year to 31 March 2017 GBPm GBPm GBPm GBPm GBPm
--------------------------------------- -------------------- ------------- -------------- ------------ -------
Operating profit for reportable
segments from continuing operations 10.9 13.8 13.3 - 38.0
Acquisition related costs - (0.3) - - (0.3)
Restructuring costs - - (0.4) - (0.4)
Restructuring costs - relating
to associate - (0.4) - - (0.4)
Impairment of capitalised development
costs (0.7) - - - (0.7)
Loss on disposal of subsidiary - (0.4) - - (0.4)
Impairment of investment in
associate - (8.0) - - (8.0)
Impairment of capitalised software
costs - - - (2.2) (2.2)
Amortisation of acquired intangibles (2.9) (7.7) (1.9) - (12.5)
Impairment of acquired intangibles (22.6) - (11.2) - (33.8)
Financial income - - - 1.4 1.4
Financial expenditure - - - (6.9) (6.9)
--------------------------------------- -------------------- ------------- -------------- ------------ -------
Loss before income tax from
continuing operations (15.3) (3.0) (0.2) (7.7) (26.2)
--------------------------------------- -------------------- ------------- -------------- ------------ -------
Notes on the Half Year Financial Statements (continued)
Half year ended 30 September 2017 - unaudited
4 RESEARCH AND DEVELOPMENT
The total research and development spend by the Group is as follows:
Half year Half year Year to
to to
30 Sept 30 Sept 31 March
2017 2016 2017
GBPm GBPm GBPm
-------------------------------------------------- ---------- ---------- ---------
Research and development expense charged
to the consolidated statement of income 11.4 12.1 24.3
Less: depreciation of R&D related fixed
assets - - (0.1)
Add: amounts capitalised as fixed assets 0.1 0.1 0.2
Less: amortisation and impairment of
R&D costs previously capitalised as intangibles (1.6) (2.2) (4.5)
Add: amounts capitalised as intangible
assets 3.1 3.0 5.9
Total cash spent on research and development
during the period 13.0 13.0 25.8
-------------------------------------------------- ---------- ---------- ---------
5 INVESTMENT IN ASSOCIATE
The Group's share of loss in its equity accounted associate, Scienta Scientific AB ("Scienta"), for the period was GBP0.3m (2016/17 half year: GBP0.5m loss; full year: GBP1.2m loss). The Group did not receive any dividends from the associate in the current or prior periods.
During the 6 months to 30 September 2017 the Group invested a further GBP2.1m in its equity accounted associate.
During the prior year the Group settled various claims totalling GBP0.4m relating to the disposal of its Omicron business during 2015/16 and recognised an impairment charge of GBP8.0m in respect of its investment in Scienta.
Notes on the Half Year Financial Statements (continued)
Half year ended 30 September 2017 - unaudited
6 DISPOSAL OF SUBSIDIARY AND DISCONTINUED OPERATIONS
On 3 July 2017 the Group disposed of its Industrial Analysis business for a final consideration of GBP82.8m. On 17 November 2016 the Group disposed of its Superconducting Wire business for a final consideration of GBP14.0m.
Industrial Superconducting
Analysis Wire
Effect of disposal on the financial position of the
Group 2017/18 2016/17
GBPm GBPm
----------------------------------------------------- ----------- ----------------
Goodwill (4.3) -
Acquired intangibles (0.1) -
Other intangibles (4.7) -
Property, plant and equipment (2.4) (3.1)
Inventory (11.3) (12.6)
Trade and other receivables (16.4) (6.5)
Cash and cash equivalents (6.0) (0.3)
Trade and other payables 14.9 6.6
Provisions 0.8 0.1
Tax balances (0.1) -
----------------------------------------------------- ----------- ----------------
Net assets divested (29.6) (15.8)
----------------------------------------------------- ----------- ----------------
Consideration receivable 82.8 14.0
Deferred consideration - (1.0)
Refund due in respect of finalisation of working
capital adjustment 0.6 -
----------------------------------------------------- ----------- ----------------
Consideration received, satisfied in cash 83.4 13.0
Cash disposed of (6.0) (0.3)
Transaction expenses (4.4) (0.5)
----------------------------------------------------- ----------- ----------------
Net cash inflow 73.0 12.2
----------------------------------------------------- ----------- ----------------
Carrying value of net assets disposed of (excluding
cash and cash equivalents) (23.6) (15.5)
Deferred consideration - 1.0
Refund due in respect of finalisation of working
capital adjustment (0.6) -
Recognition of provisions on disposal (2.8) (0.2)
Currency translation differences transferred from
translation reserve 4.8 5.7
----------------------------------------------------- ----------- ----------------
Gain on disposal 50.8 3.2
Tax (charge)/credit on gain on disposal (3.8) 0.9
----------------------------------------------------- ----------- ----------------
Gain on disposal net of tax 47.0 4.1
----------------------------------------------------- ----------- ----------------
Discontinued operations
In the period to 30 September 2017 the Group's Industrial Analysis business was classified as a discontinued operation; and in the year to 31 March 2017 the Group's Superconducting Wire business was classified as a discontinued operation. They were considered major classes of business on the basis that they were previously operating segments and referred to in the Group Strategic Report.
The Group results have been re-presented to reflect the classification of the Group's Industrial Analysis and Superconducting Wire businesses as discontinued operations.
Notes on the Half Year Financial Statements (continued)
Half year ended 30 September 2017 - unaudited
6 DISPOSAL OF SUBSIDIARY AND DISCONTINUED OPERATIONS continued
Industrial Superconducting
Results of discontinued operations
- half year to 30 Sep 2017 Analysis Wire Total
GBPm GBPm GBPm
-------------------------------------------- ----------- ---------------- -------
Revenue 16.8 - 16.8
Expenses (16.1) - (16.1)
-------------------------------------------- ----------- ---------------- -------
Adjusted profit before tax 0.7 - 0.7
Income tax charge (0.4) - (0.4)
-------------------------------------------- ----------- ---------------- -------
Adjusted profit after tax 0.3 - 0.3
-------------------------------------------- ----------- ---------------- -------
Adjusting items:
Amortisation and impairment of acquired
intangibles (0.1) - (0.1)
One off costs arising as a result
of disposal (2.2) - (2.2)
Property sale costs - (0.2) (0.2)
Income tax on adjusting items 0.8 - 0.8
-------------------------------------------- ----------- ---------------- -------
Loss after tax (1.2) (0.2) (1.4)
-------------------------------------------- ----------- ---------------- -------
Gain on disposal 50.8 - 50.8
Tax on gain on disposal (3.8) - (3.8)
-------------------------------------------- ----------- ---------------- -------
Profit/(loss) from discontinued operations
after tax 45.8 (0.2) 45.6
-------------------------------------------- ----------- ---------------- -------
The one off costs arising as a result of the disposal comprise a GBP1.8 million impairment of capitalised development costs in respect of a project which was discontinued as a result of the sale of the Industrial Analysis division along with related on-going costs incurred in the current year.
The property sale costs relate to the ongoing sale of a surplus freehold property.
Industrial Superconducting
Results of discontinued operations
- half year to 30 Sep 2016 Analysis Wire Total
GBPm GBPm GBPm
-------------------------------------------- ----------- ---------------- -------
Revenue 20.8 18.3 39.1
Expenses (19.3) (17.2) (36.5)
-------------------------------------------- ----------- ---------------- -------
Adjusted profit before tax 1.5 1.1 2.6
Income tax charge (0.3) (0.4) (0.7)
-------------------------------------------- ----------- ---------------- -------
Adjusted profit after tax 1.2 0.7 1.9
-------------------------------------------- ----------- ---------------- -------
Adjusting items:
Amortisation and impairment of acquired
intangibles (2.1) - (2.1)
Acquisition related costs (0.4) - (0.4)
Income tax on adjusting items 0.4 - 0.4
-------------------------------------------- ----------- ---------------- -------
(Loss)/profit from discontinued operations
after tax (0.9) 0.7 (0.2)
-------------------------------------------- ----------- ---------------- -------
Industrial Superconducting Austin
Results of discontinued operations
- full year to 31 Mar 2017 Analysis Wire Scientific Total
GBPm GBPm GBPm GBPm
-------------------------------------------- ----------- ---------------- ----------- -------
Revenue 48.3 22.2 - 70.5
Expenses (43.8) (20.9) (0.2) (64.9)
-------------------------------------------- ----------- ---------------- ----------- -------
Adjusted profit/(loss) before tax 4.5 1.3 (0.2) 5.6
Income tax charge (0.9) (0.4) - (1.3)
-------------------------------------------- ----------- ---------------- ----------- -------
Adjusted profit/(loss) after tax 3.6 0.9 (0.2) 4.3
-------------------------------------------- ----------- ---------------- ----------- -------
Adjusting items:
Amortisation and impairment of acquired
intangibles (2.4) - - (2.4)
Acquisition related costs (1.2) - - (1.2)
Restructuring costs (0.2) - - (0.2)
Income tax on adjusting items 0.6 - - 0.6
-------------------------------------------- ----------- ---------------- ----------- -------
Profit/(loss) after tax 0.4 0.9 (0.2) 1.1
-------------------------------------------- ----------- ---------------- ----------- -------
Gain on disposal - 3.2 - 3.2
-------------------------------------------- ----------- ---------------- ----------- -------
Tax on gain on disposal - 0.9 - 0.9
-------------------------------------------- ----------- ---------------- ----------- -------
Profit/(loss) from discontinued operations
after tax 0.4 5.0 (0.2) 5.2
-------------------------------------------- ----------- ---------------- ----------- -------
Notes on the Half Year Financial Statements (continued)
Half year ended 30 september 2017 - unaudited
6 DISPOSAL OF SUBSIDIARY AND DISCONTINUED OPERATIONs continued
Earnings per share from discontinued operations
Half year Half year Year to
to to
30 Sept 30 Sept 31 March
2017 2016 2017
GBPm GBPm GBPm
------------------------------------- ---------- ---------- ---------
Adjusted basic earnings per share 0.5 3.4 7.5
Adjusted diluted earnings per share 0.5 3.3 7.5
Total basic earnings per share 79.9 (0.4) 9.1
Total diluted earnings per share 79.5 (0.4) 9.1
------------------------------------- ---------- ---------- ---------
Cash flows from discontinued operations
Half year Half year Year to
to to
30 Sept 30 Sept 31 March
2017 2016 2017
GBPm GBPm GBPm
--------------------------------------- ---------- ---------- ---------
Net cash generated from operating
activities 2.4 1.9 6.1
Net cash used in investing activities (0.5) (1.3) (2.5)
Net cash used in financing activities - - -
Net cash flows 1.9 0.6 3.6
--------------------------------------- ---------- ---------- ---------
7 TAXATION
The total effective tax rate on profits for the half year is 21.3% (2016/17: 16.7%). The weighted average tax rate in respect of adjusted profit before tax (see note 2) for the half year is 22.1% (2016/17: 21.4%). For the full year the Group expects the tax rate in respect of adjusted profit before tax to be 23.0%.
8 earnings per share a) Basic
The calculation of basic earnings per share is based on the profit or loss for the period after taxation and a weighted average number of ordinary shares outstanding during the period, excluding shares held by the Employee Share Ownership Trust, as follows:
Half year Half year Year to
to to
30 Sept 30 Sept 31 March
2017 2016 2017
Shares Shares Shares
million million million
------------------------------------------ ---------- ---------- ---------
Weighted average number of shares
outstanding 57.3 57.3 57.3
Less: weighted average number of
shares held by Employee Share Ownership
Trust (0.2) (0.2) (0.2)
------------------------------------------ ---------- ---------- ---------
Weighted average number of shares
used in calculation of earnings
per share 57.1 57.1 57.1
------------------------------------------ ---------- ---------- ---------
Notes on the Half Year Financial Statements (continued)
Half year ended 30 september 2017 - unaudited
8 earnings per share continued b) Diluted
The following table shows the effect of share options on the calculation of both adjusted and unadjusted diluted basic earnings per share.
Half year Half year Year to
to to
30 Sept 30 Sept 31 March
2017 2016 2017
Shares Shares Shares
million million million
--------------------------------------- ---------- ---------- ---------
Number of ordinary shares per basic
earnings per share calculations 57.1 57.1 57.1
Effect of shares under option 0.3 0.1 0.1
--------------------------------------- ---------- ---------- ---------
Number of ordinary shares per diluted
earnings per share calculations 57.4 57.2 57.2
--------------------------------------- ---------- ---------- ---------
9 dividends per share
The following dividends per share were paid by the Group:
Half year Half year Year to
to to
30 Sept 30 Sept 31 March
2017 2016 2017
pence pence pence
---------------------------------- ---------- ---------- ---------
Previous period interim dividend 3.70 3.70 3.70
Previous period final dividend - - 9.30
---------------------------------- ---------- ---------- ---------
3.70 3.70 13.00
---------------------------------- ---------- ---------- ---------
The following dividends per share were proposed by the Group in respect of each accounting period presented:
Half year Half year Year to
to to
30 Sept 30 Sept 31 March
2017 2016 2017
pence pence pence
------------------ ---------- ---------- ---------
Interim dividend 3.70 3.70 3.70
Final dividend - - 9.30
------------------ ---------- ---------- ---------
3.70 3.70 13.00
------------------ ---------- ---------- ---------
The final dividend for the year to 31 March 2017 was approved by shareholders at the Annual General Meeting held on 12 September 2017. Accordingly it is no longer at the discretion of the company and has been included as a liability as at 30 September 2017. It was paid on 19 October 2017.
The interim dividend for the year to 31 March 2017 of 3.70 pence was approved by the Board on 14 November 2017 and has not been included as a liability as at 30 September 2017. The interim dividend will be paid on 6 April 2018 to shareholders on the register at the close of business on 23 February 2018.
Notes on the Half Year Financial Statements (continued)
Half year ended 30 september 2017 - unaudited
10 FAIR value of financial instruments
The fair values of financial assets and liabilities together with the carrying amounts shown in the Consolidated Statement of Financial Position are as follows:
Carrying Fair Carrying Fair Carrying Fair
amount value amount value amount value
Fair 30 Sept 30 Sept 30 Sept 30 Sept 31 March 31 March
value 2017 2017 2016 2016 2017 2017
hierarchy GBPm GBPm GBPm GBPm GBPm GBPm
---------------------------------- ---------- -------- -------- -------- -------- --------- ---------
Assets carried at amortised cost
Trade receivables 53.4 51.6 69.2 69.2 70.6 70.6
Other receivables 11.1 11.1 6.4 6.4 7.6 7.6
Cash and cash equivalents 14.3 14.3 20.9 20.9 27.2 27.2
---------------------------------- ---------- -------- -------- -------- -------- --------- ---------
Assets carried at fair value
Derivative financial instruments:
- Foreign currency contracts 2 2.3 2.3 - - 0.6 0.6
---------------------------------- ---------- -------- -------- -------- -------- --------- ---------
Liabilities carried at fair value
Derivative financial instruments:
- Foreign currency contracts 2 (1.0) (1.0) (10.9) (10.9) (5.0) (5.0)
Liabilities carried at amortised
cost
Trade and other payables (54.1) (54.1) (55.9) (55.9) (82.4) (82.4)
Bank overdraft (0.6) (0.6) (1.8) (1.8) (1.4) (1.4)
Borrowings (59.2) (59.2) (160.2) (160.2) (148.6) (148.6)
---------------------------------- ------ ------ ------- ------- ------- -------
The following summarises the major methods and assumptions used in estimating the fair values of financial instruments reflected in the above table.
Derivative financial instruments
Derivative financial instruments are marked-to-market using market prices.
Fixed and floating rate borrowings
The fair value of fixed and floating rate borrowings is estimated by discounting the future contracted principal and interest cash flows using the market rate of interest at the reporting date.
Trade and other receivables/payables
For receivables/payables with a remaining life of less than one year, the carrying amount is deemed to reflect the fair value. All other receivables/payables are discounted to determine their fair value. Advances received are excluded from other payables above as these are not considered to be financial liabilities.
Contingent consideration
The fair value of contingent consideration is estimated based on the forecast future performance of the acquired business over a timeframe determined as part of the acquisition agreement, discounted as appropriate. Key assumptions include growth rates, expected selling volumes and prices and direct costs during the period.
Notes on the Half Year Financial Statements (continued)
Half year ended 30 September 2017 - unaudited
10 FAIR value of financial instruments continued
Fair value hierarchy
The table above gives details of the valuation method used in arriving at the fair value of financial instruments. The different levels have been identified as follows:
Level 1: quoted prices (unadjusted) in active markets for identical assets and liabilities;
Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
Level 3: inputs for the asset or liability that are not based on observable market data.
There have been no transfers between levels during the year.
Contingent consideration relates to amounts payable in respect of acquisitions. It is reassessed at the end of each year to its fair value.
30 Sep 2017 30 Sep 2016 31 Mar 2017
Contingent consideration GBPm GBPm GBPm
---------------------------------------------------------- ----------- ----------- -----------
Balance brought forward at beginning of period - 6.6 6.6
Fair value of contingent consideration on acquisitions - -
in the year -
Unwind of discount in respect of contingent consideration - - -
Contingent consideration paid - (6.5) (6.5)
Increase in contingent consideration - - -
Contingent consideration released to the consolidated - - statement of income - Effect of movement in foreign exchange - (0.1) (0.1) ---------------------------------------------------------- ----------- ----------- ----------- Balance carried forward at end of period - - - ---------------------------------------------------------- ----------- ----------- ----------- 11 RELATED PARTIES
All transactions with related parties are conducted on an arm's length basis and in accordance with normal business terms. Transactions between related parties that are Group subsidiaries are eliminated on consolidation.
During the period, the Group supplied services and materials to its associate, Scienta Omicron Gmbh, on an arm's length basis. The following transactions occurred during the period:
Revenue Receivables
Half year to 30 September 2017 GBPm GBPm
-------------------------------- -------- ------------
Scienta Omicron GmbH - 3.6
-------------------------------- -------- ------------
Revenue Receivables
Half year to 30 September 2016 GBPm GBPm
-------------------------------- -------- ------------
Scienta Omicron GmbH 0.1 3.6
-------------------------------- -------- ------------
Included in receivables is a non-current loan receivable of GBP2.1m (2016: GBP3.6m) and a current loan receivable of GBP1.5m (2016: GBPnil). The loan is repayable at the end of May 2020. During the period the Group received interest charged on the loan of GBP0.1m (2016: GBP0.1m).
Principal Risks and Uncertainties
The Group has in place a risk management structure and internal controls which are designed to identify, manage and mitigate risk.
In common with all businesses, Oxford Instruments faces a number of risks and uncertainties which could have a material impact on the Group's long term performance.
On pages 23 to 25 of its 2017 Annual Report and Accounts (a copy of which is available at www.oxford-instruments.com), the Company set out what the Directors regarded as being the principal risks and uncertainties facing the Group's long term performance and these are reproduced in the table below. Many of these risks are inherent to Oxford Instruments as a global business and they remain valid as regards their potential impact during the remainder of the second half of the year.
The impact of the economic and end market environments in which the Group's businesses operate are considered in the Half Year Statement of this Half Year Report, together with an indication if management is aware of any likely change in this situation.
ID Specific Risk Context Risk Possible Impact Control Mitigation
Mechanisms
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
1 Technical Risk The Group Failure of the Lower returns 'Voice of the Understanding
provides high advanced through loss of Customer' customer needs /
technology technologies market share & approach to expectations and
equipment and applied by the reduced drive the targeted new
systems to its Group to profitability. product product development
customers. produce development road programme
commercial Negative impact map; to maintain and
products, on the Group's strengthen product
capable of reputation. Formal new positioning.
being product
manufactured development Stage gate process
and sold stage gate in product
profitably. process to development to
manage R&D challenge
commercial business
Product case and mitigate
lifecycle technical risks.
management
Operational
practices around
sales-production
matching and
inventory
management to
mitigate
stock obsolescence
risks.
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
2 Routes to market In some Backward Loss of a key Customer Product
instances the vertical route to market; intimacy to differentiation to
Group's integration by new competitors; match product promote advantages
products are OEMs lower sales and performance to of OI equipment &
components of profitability. customer needs; solutions;
higher level
systems, sold Strategic marketing
by OEMs Positioning of with OEMs to sell
and thus the OI brand and performance of the
Group does not marketing combined system;
control its directly to end
route to users Broadening the OEM
market. customer base;
Direct marketing to
end users
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
3 Economic Government Reduction in Lower sales and Market intimacy Market
environment expenditure may global research profitability and diversification -
become funding identification increasing
constrained in of alternative penetration into
key markets markets corporate customers
not dependent on
external funding
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
4 Political risk The Group Geopolitical Lower sales and Contract review Broad global
operates in changes profitability and protection customer base;
global markets resulting in against breach contractual
and can be sanctions and in the event protection
required to bar on exports that export
secure export to specific licence is
licences from countries or withheld
governments. unfavourable
changes in
tariffs / other
controls on
exports
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
5 Brexit related The UK will Short-term Lower sales and Market intimacy Market
risks leave the EU decline in profitability and diversification -
European identification increasing
research of alternative penetration into
funding; Salary markets corporate customers
inflation; not dependent on
Increased input Procurement external funding
costs; strategy to
Inflationary reduce price Long term pricing
pressure on volatility agreements for key
purchases and suppliers
salaries; Loss of key Product pricing
skills / strategy Margin focused
increased sales targets to
recruitment / HR people mitigate potential
salary costs strategy to increases in costs
facilitate
Possible recruitment & Renewal of UK work
changes to EU retention of permit scheme to
citizens' staff with key facilitate
rights to work skills employment of non
in UK impacting UK / EU nationals
retention &
recruitment.
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
6 Supply chain The Group Supply chain Disruption to Procurement Buffer stocks of
risk operates a disruption in customers. strategy to key components;
strategic make particular for manage stock
or buy policy single source Lower sales and availability Where possible,
and outsources components profitability dual source supply
a significant leading to is sought
proportion production Negative impact
of the costs of delays and on the Group's
production to potentially reputation.
benefit from lost revenue.
economies of
scale and
natural
currency
hedges.
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
7 People A number of the Key employees Lower sales and HR people Succession
Group's leave and profitability strategy for management plans;
employees have effective retention & Technical career
business replacements recruitment of paths;
critical are not staff with key Renewal of UK work
skills. recruited on a skills permit scheme to
timely basis facilitate
employment of non
UK / EU nationals
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
8 IT risk Elements of Increasing risk Loss of business IT security On-going evolution
production, of data loss / critical data policy & of security levels
financial and breach through and / or associated in consultation
other systems cyber-attack, financial loss standards and with IT security
rely on IT viruses or protection partners to ensure
availability malware. systems. changes are in-line
with current
"Zero-day" Internal IT threats.
incidents, governance to
where new maintain those Inter alia, we
viruses or protection deliver user
malware can systems and our education, improved
spread before incident configuration,
security response internal testing
vendors can and new tools
respond where appropriate.
represent a
particularly
high risk
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
9 Operational risk Business units' Loss of all or Delayed Business Principal sites
production part of a major shipments Continuity Plans have detailed BCPs
facilities are production leading to lower in place which include plans
typically facility sales and to restore or
located at a profitability relocate production
single site in
Use of the event of a
contractual major incident.
protection to
mitigate Mechanisms such as
financial clauses for
consequences of limitation of
delayed delivery liability /
liability caps /
exclusion of
consequential
losses in sales
contracts
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
10 Pensions The Group's Movements in Additional cash Regular review The Group has
calculated the actuarial required by the of investment closed its defined
pension deficit assumptions may Group to fund strategy. benefit pension
is sensitive to have an the deficit. schemes in the UK
changes in the appreciable Reduction in net Liability and US to future
actuarial effect on the assets. hedging accrual.
assumptions. reported programme to
pension mitigate The Group has a
deficit. exposure to funding plan in
movements in place to reduce the
interest rates pension deficit
and inflation over the short to
medium
term.
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
11 Foreign exchange The Group's Adverse foreign Reduced Natural hedging Strategic
volatility sterling cost currency profitability to offset procurement in USD,
basis is higher movements foreign currency Euros & Yen.
than its sales through
sterling procurement in
revenue sources foreign
meaning that a currencies;
significant
proportion of Hedging
the Group's programme Short-term exposure
profit is made to volatility is
in foreign managed by hedging
currencies. programme (forward
contracts)
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
12 Legal / The Group Infringement of Potential loss Formal 'Freedom Confirmation of
compliance risk operates in a a third party's of future to Operate' 'Freedom to
complex intellectual revenue; assessment to Operate' during new
technological property identify product development
environment and financial potential IP stage gate process
competitors may compensation issues during
seek to protect product
their position development;
through
intellectual
property rights
--- ----------------- ---------------- ---------------- ----------------- ----------------- --------------------
Responsibility Statement of the Directors in respect of the Half Year Financial Statements
We confirm that to the best of our knowledge:
-- the condensed set of financial statements has been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the EU;
-- the interim management report includes a fair review of the information required by:
(a) DTR 4.2.7R of the Disclosure Guidance and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and
(b) DTR 4.2.8R of the Disclosure Guidance and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the entity during that period; and any changes in the related party transactions described in the last annual report that could do so.
Ian Barkshire, Chief Executive Gavin Hill, Group Finance Director
14 November 2017
Independent review report to Oxford Instruments plc
Introduction
We have been engaged by the company to review the condensed set of financial statements in the half-yearly financial report for the six months ended 30 September 2017 which comprises the Condensed Consolidated Statement of Income, the Condensed Consolidated Statement of Comprehensive Income, Condensed Consolidated Statement of Financial Position, Condensed Consolidated Statement of Changes in Equity, Condensed Consolidated Statement of Cash Flows and the related explanatory notes.
We have read the other information contained in the half-yearly financial report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements.
This report is made solely to the company in accordance with the terms of our engagement to assist the company in meeting the requirements of the Disclosure Guidance and Transparency Rules ("the DTR") of the UK's Financial Conduct Authority ("the UK FCA"). Our review has been undertaken so that we might state to the company those matters we are required to state to it in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company for our review work, for this report, or for the conclusions we have reached.
Directors' responsibilities
The half-yearly financial report is the responsibility of, and has been approved by, the directors. The directors are responsible for preparing the half-yearly financial report in accordance with the DTR of the UK FCA.
The annual financial statements of the group are prepared in accordance with IFRSs as adopted by the EU. The condensed set of financial statements included in this half-yearly financial report has been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the EU.
Our responsibility
Our responsibility is to express to the company a conclusion on the condensed set of financial statements in the half-yearly financial report based on our review.
Scope of review
We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Auditing Practices Board for use in the UK. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK and Ireland) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Conclusion
Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the six months ended 30 September 2017 is not prepared, in all material respects, in accordance with IAS 34 as adopted by the EU and the DTR of the UK FCA.
Greg Watts
for and on behalf of KPMG LLP
Chartered Accountants
One Snowhill, Snow Hill Queensway
Birmingham, B4 6GH
14 November 2017
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR LFFEILILVLID
(END) Dow Jones Newswires
November 14, 2017 02:01 ET (07:01 GMT)
1 Year Oxford Instruments Chart |
1 Month Oxford Instruments Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
